Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $25.00

Sage Therapeutics (NASDAQ:SAGE) had its price target decreased by analysts at HC Wainwright from $28.00 to $25.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 82.62% from the stock’s current price. HC Wainwright also issued estimates for Sage Therapeutics’ Q1 2025 earnings at ($1.62) EPS, Q2 2025 earnings at ($1.59) EPS, Q3 2025 earnings at ($1.13) EPS and Q4 2025 earnings at ($1.15) EPS.

A number of other equities analysts have also recently issued reports on SAGE. Morgan Stanley increased their target price on Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. Canaccord Genuity Group dropped their target price on Sage Therapeutics from $21.00 to $17.00 and set a “hold” rating for the company in a report on Friday. StockNews.com cut Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, April 19th. JPMorgan Chase & Co. raised their price target on Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, March 26th. Finally, Royal Bank of Canada dropped their price target on Sage Therapeutics from $26.00 to $15.00 and set a “sector perform” rating for the company in a report on Friday. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $37.72.

Sage Therapeutics Stock Up 0.8 %

Sage Therapeutics stock opened at $13.69 on Friday. The business has a 50 day moving average price of $18.56 and a two-hundred day moving average price of $20.64. The stock has a market cap of $823.86 million, a price-to-earnings ratio of -1.63 and a beta of 0.86. Sage Therapeutics has a 12 month low of $10.92 and a 12 month high of $59.99.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). Sage Therapeutics had a negative return on equity of 54.17% and a negative net margin of 552.52%. The company had revenue of $7.90 million during the quarter, compared to analyst estimates of $5.26 million. During the same period in the previous year, the company posted ($2.46) earnings per share. The company’s quarterly revenue was up 139.4% on a year-over-year basis. On average, analysts expect that Sage Therapeutics will post -6.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. CWM LLC boosted its position in Sage Therapeutics by 274.2% in the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 883 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Sage Therapeutics by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 748 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Sage Therapeutics by 17.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,289 shares of the biopharmaceutical company’s stock worth $191,000 after purchasing an additional 1,375 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Sage Therapeutics in the 3rd quarter worth $219,000. Finally, Quest Partners LLC bought a new position in shares of Sage Therapeutics in the 4th quarter worth $261,000. 99.22% of the stock is currently owned by institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.